MET and colorectal carcinoma: Conversely, silencing c‐Met significantly reduced three features of CRC stemness [18, 19], the CD133 expression levels, the spheroid formation, and the drug resistance, upon B7‐H3 overexpression (Figure 4D,E, Figure S3A,B).